	two enantiomer	10.558157000214454
	one enantiomer	10.558156970304054
	racemate PCR	7.542334203700115
	pure dextrorotatory enantiomer	7.394502782437506
	either dextrorotatory enantiomer	7.362222217424588
	separate enantiomer	7.040397194479103
	pure levorotatory enantiomer	5.9491339339327975
	compound designate PCR	3.986711288298144
	dextrorotatory isomer	3.0772636763224277
¡°	pharmaceutical product clopidogrel bisulfate	2.7324958756055455
	chiral thienopyridine	2.5878843005439496
	racemate PRC	2.480640161317671
	specific racemate	2.2697790747051507
	know racemate	2.269576022523912
	unusual stereoselectivity	1.7110847230899575
	absolute stereoselectivity	1.7089008509096208
	two thienopyridine	1.6387635920937276
	generic clopidogrel	1.58095016618171
	thus separation	1.3497400020610126
	common name ticlopidine	1.1380423087087834
	bisulfate salt	1.082340046012115
	one asymmetric carbon atom	0.9046917723589123
	describ[ing asymmetric molecule	0.8482103319592135
	spatial isomer	0.8350891030817298
	scientist	0.7989612547581009
	thrombotic thrombocytopenic purpura	0.7871321978198047
	Louis Pasteur	0.7294604378254907
	several hundred additional thienopyridine derivative	0.6801586639347821
	eventually successful separation	0.6800808199038468
	first separation	0.6748699686410938
	favorable antiplatelet activity	0.6578755589383993
	anda)1	0.6332203595470106
	neutropenia	0.6332203595470106
	-COOCH3	0.6332203595470106
	acetone	0.6332203595470106
	tabletting	0.6332203595470106
	levoenantiomer	0.6332203595470106
	enantiomeric form	0.6329902899283335
	Synthelabo	0.5934596788866383
	least ten separation technique	0.5604396219521894
	stereoisomer	0.5358187190000319
	blood platelet aggregation	0.5244504032470348
	reagent	0.5090465673841744
	dextro rotatory isomer	0.4719430727016475
	acronym MATTPCA	0.4498581141801452
	significant neurotoxicity	0.42409985275808815
	ï¿½ï¿½	0.422012621417135
	levo rotatory isomer	0.39894604161424135
	compound MATTPCA	0.3960503096326706
	Hydrogen sulfate	0.37551058306296825
	successful experiment	0.37277850193642614
	Clopidogrel	0.3652582457396717
	Y.	0.3652582457396717
	chlorine	0.3652582457396717
	convulsion	0.3652582457396717
	camphorsulfonic acid	0.3580193846554821
	Chiral	0.3166101797735053
	optimum anti platelet aggregation property	0.30539225523005603
	separate isomer	0.30136873527851554
	counterpart	0.30086502186751696
	plane polarize light	0.29391674798383166
	spatial orientation	0.28911592107449174
	blood thrombotic event	0.2845210029660432
	good anti platelet aggregation property	0.2844425872840295
	spatial arrangement	0.26066124517964456
	bridge carbon atom	0.2580209714653525
	France	0.2517734193934478
	one carbon atom	0.24374137086924788
	isomeric compound	0.24213847135987654
	improved platelet inhibition	0.24188106057035927
	anti thrombotic agent	0.24184590866275565
	carbon bond	0.23389428154480182
	asymmetrical carbon	0.23100900631590326
	thiene ring	0.2240385492437578
	carboxylic acid	0.22403832775181262
	hydrogen sulfate salt	0.21272010485013687
	tetrahedral structure	0.21123251357161965
	lucky combination	0.21120895836931894
	Hawley Condensed Chemical Dictionary	0.20923939077389483
	stroke	0.19295359238392396
	Educ	0.19295359238392396
	ante	0.18047048499739038
	methyl ester group	0.17606304933138023
	whose maleate salt	0.17448057176726153
	hydrochloride salt	0.1673885856327254
	toxicity profile	0.16389127906287615
	toxicity concern	0.1507506984744008
	four different substituent	0.1503287586765325
	undue experimentation	0.14945125388964003
	hydrogen atom	0.14547266598809075
	different biological activity	0.14039152456757145
	biological property	0.13867993777846613
	amide group	0.13029603686951718
	optically pure form	0.12697381305467842
	dollar	0.12047880801549561
	methyl group	0.10891105390466131
	prolonged usage	0.10786908165624831
	addition salt	0.10719384903615327
	pyridine ring	0.09783791878643516
	Sr	0.09647679619196198
	chemical name methyl	0.0913033473022704
	diverse salt form composition	0.08683946677595528
	optical activity	0.0841468400901253
	various solvent	0.06852132793262045
	anti inflammatory property	0.06615901512557099
	X	0.060261931834832416
	Geneva Pharms	0.05722423136497917
	Hoechst Marion Roussel Inc.	0.05457946476929183
	beneficial property	0.04820302936056769
	invalidation	0.047903277025820326
	specific compound	0.04691607712103492
	certain compound	0.04664845558860464
	FDA approval	0.04565718835113474
	irreparable harm	0.04431460276381227
	chemical compound	0.043966326273200386
	hardship	0.04307709886528457
	benzene component	0.04242609800741335
	Phase human trial	0.04117559861647348
	laboratory animal	0.040806398309369774
	adverse property	0.03946683545159036
	serious blood disorder	0.03868361561200013
	therapeutic benefit	0.036993264190229656
	purified solution	0.03652571280386017
	mirror image	0.034560725415081046
	More year	0.034361881883445376
	ten million	0.03430555326407415
	optical characteristic	0.033234586876638966
	chemical literature	0.030843120380892996
	thirty composition	0.030497976106793608
	one month crystal	0.030247050348339983
	require warning	0.030130969181075794
	Schering Corp.	0.030130966230684997
	various resolve acid	0.028015500077655187
	several hundred chemical modification	0.027763600447781606
	minimal undesirable effect	0.02669134321152893
	french priority filing	0.025868231120186297
	relevant herein	0.025804122570909072
	lengthy development	0.02305209251561894
	potential replacement	0.02292576994922985
	isolation	0.022784570928572657
	Merck	0.022784570928572657
	rare characteristic	0.022118804437986455
	Teva Pharms	0.021729342454628823
	Amgen Inc.	0.021024778470960823
	undesirable side effect	0.020543431947969627
	mixture	0.020251917529125883
	various concentration	0.01968975173188105
	processing	0.01945491695896212
	thirty seven possibility	0.019093249689460162
	possible adverse effect	0.018045178938987935
	usual case	0.017853297018702474
	possession	0.016736698409633013
	thirty month stay	0.016695848061219747
	chemical formula	0.016493074599110074
	paragraph iv certification	0.01594440890639892
	identical almost identical chemical physical property	0.01585995188652196
	general class	0.015499386463058802
	animal human trial	0.01518102383099217
	three dimensional space	0.014805526914930617
	introduction	0.014490376303392076
	propose settlement	0.014465686131331083
	Hatch Waxman Act	0.013546000486299586
	double patenting	0.013536456780670695
	heart attack	0.012887129841486064
	belief	0.012609876761318368
	following structural formula	0.010873405674065653
	Newman	0.010336215151708378
	chemical structure	0.009795368805543993
	preliminary injunction	0.009216051062184448
	nonobviousness	0.008254852865474156
	five month	0.008215833065752295
	unenforceability	0.00803247886980455
	advance	0.007861805590797275
	research effort	0.007708679931101445
	patented pharmaceutical product	0.00765564659651033
	twenty one example	0.007258560803672615
	high dose	0.007111835074896485
	anticipation	0.006669856175199447
	statutory procedure	0.006385104195454734
	clinical commercial development	0.0060928577107824886
	statutory stay	0.005900513293704495
	Abbreviated New Drug Application	0.00538884542758112
	equal amount	0.005350039555306455
	generic form	0.0052305301793362765
	pre marketing legal challenge	0.0051937514970575695
	substantive issue	0.005187204922940866
	February	0.004487879232009876
	neither twenty one specific example	0.004275099916849217
	United States Food Drug Administration	0.004195550737004718
	New York	0.003893837985747899
	equitable factor	0.0037368725498220933
	Research	0.003605456488427154
	accordance	0.0033056424150683787
	extensive expert testimony	0.0032735970238706087
	following general structure	0.003241507646463595
	Southern District	0.003032044080191604
	expert witness	0.0027405482771235123
	condition	0.002704040587323535
	November	0.0024471957460881696
	related company	0.0020714564639977956
	Med	0.0019250519475629644
	July	0.0017293286204908736
	report	0.0015721637032392
	August	0.0013525259108718344
	hand	0.0011646187014084123
	USA Inc.	0.0010477173189570325
	various public interest	0.001002609424417834
	bench trial	0.0008639337097896058
	April	0.0008232575096466167
	January	0.0006755692328057573
	line	0.000501889878131648
	early opinion	0.00046015715702641763
	anticipate reference	0.0004485820767118891
	sale	0.0004112446517569887
	litigation purpose	0.0003757851638534685
	district court ruling sustain validity	0.00035660679703886474
	owner	0.0003365035789144462
	patentability	0.00024817953579665624
	full trial	0.00020534593684423991
	ordinary skill	0.00012181227210533893
	background	0.00012146809599389561
	every element	0.00010835007296777705
	several ground	8.60351535699743e-05
	holding	6.243027292982544e-05
	clear error	4.5563464697083396e-05
	suit	3.906647242542964e-05
	infringe product	3.090315736619398e-05
	view	2.558605497315114e-05
	United States examiner	1.146334762577847e-05
	Claim	9.694320132413497e-06
	either reference	8.46871790423921e-06
	limitation	6.610380560270145e-06
	district court finding	5.722473425392914e-06
	single prior art reference	5.415116707115114e-06
	subject matter	5.16453198134531e-06
	record	6.904802404382686e-07
	application	4.6032016029217907e-07
	law	1.9406537326207762e-07
	state	1.1092539711011776e-07
	infringement action	9.258554851900865e-08
	use	3.925130242377641e-09
	invention	3.6699423124317224e-09
	Court	0.0
	Appeals	0.0
	Fed	0.0
